BR9911754A - Copolìmero linear de ciclodextrina, composição terapêutica, composição de ciclodextrina, processos de preparo de um copolìmero linear de ciclodextrina, e de um copolìmero linear de ciclodextrina oxidada, processo para produzir um polìmero reticulado de ciclodextrina, e, processo de tratamento - Google Patents

Copolìmero linear de ciclodextrina, composição terapêutica, composição de ciclodextrina, processos de preparo de um copolìmero linear de ciclodextrina, e de um copolìmero linear de ciclodextrina oxidada, processo para produzir um polìmero reticulado de ciclodextrina, e, processo de tratamento

Info

Publication number
BR9911754A
BR9911754A BR9911754-1A BR9911754A BR9911754A BR 9911754 A BR9911754 A BR 9911754A BR 9911754 A BR9911754 A BR 9911754A BR 9911754 A BR9911754 A BR 9911754A
Authority
BR
Brazil
Prior art keywords
cyclodextrin
linear
copolymer
composition
oxidized
Prior art date
Application number
BR9911754-1A
Other languages
English (en)
Other versions
BR9911754B1 (pt
Inventor
Hector Gonzalez
Suzie Sue Jean Hwang
Mark E Davis
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Publication of BR9911754A publication Critical patent/BR9911754A/pt
Publication of BR9911754B1 publication Critical patent/BR9911754B1/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

"COPOLìMERO LINEAR DE CICLODEXTRINA, COMPOSIçãO TERAPêUTICA, COMPOSIçãO DE CICLODEXTRINA, PROCESSOS DE PREPARO DE UM COPOLìMERO LINEAR DE CICLODEXTRINA, E DE UM COPOLìMERO LINEAR DE CICLODEXTRINA OXIDADA, PROCESSO PARA PRODUZIR UM POLìMERO RETICULADO DE CICLODEXTRINA, E, PROCESSO DE TRATAMENTO". Descrevem-se copolímeros lineares de ciclodextrina e copolímeros lineares de ciclodextrina oxidada, contendo uma porção de ciclodextrina não oxidada e/ou oxidada integrada na espinha dorsal do polímero. Processos de preparo de tais copolímeros também são descritos. O copolímero linear de ciclodextrina e o copolímero linear de ciclodextrina oxidada da invenção podem ser usados como um veículo de liberação de vários agentes terapêuticos.
BRPI9911754-1A 1998-07-01 1999-06-25 copolìmero linear de ciclodextrina, solúvel em água, composição terapêutica, processo de preparo de um copolìmero linear de ciclodextrina, solúvel em água, e, processo de prepraro de um copolìmero linear de ciclodextrina oxidada, solúvel em água. BR9911754B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9155098P 1998-07-01 1998-07-01
US09/203,556 US6509323B1 (en) 1998-07-01 1998-12-02 Linear cyclodextrin copolymers
PCT/US1999/014298 WO2000001734A1 (en) 1998-07-01 1999-06-25 Linear cyclodextrin copolymers

Publications (2)

Publication Number Publication Date
BR9911754A true BR9911754A (pt) 2001-11-06
BR9911754B1 BR9911754B1 (pt) 2010-07-13

Family

ID=26784076

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9911754-1A BR9911754B1 (pt) 1998-07-01 1999-06-25 copolìmero linear de ciclodextrina, solúvel em água, composição terapêutica, processo de preparo de um copolìmero linear de ciclodextrina, solúvel em água, e, processo de prepraro de um copolìmero linear de ciclodextrina oxidada, solúvel em água.

Country Status (18)

Country Link
US (1) US6509323B1 (pt)
EP (2) EP1093469B1 (pt)
JP (2) JP4741729B2 (pt)
KR (1) KR100851315B1 (pt)
CN (1) CN100365024C (pt)
AT (1) ATE361321T1 (pt)
AU (1) AU763114C (pt)
BR (1) BR9911754B1 (pt)
CA (1) CA2336390C (pt)
CY (1) CY1106797T1 (pt)
DE (1) DE69935982T2 (pt)
DK (2) DK1764112T3 (pt)
ES (2) ES2403416T3 (pt)
HU (1) HU229473B1 (pt)
IL (2) IL140552A0 (pt)
MX (1) MXPA01000206A (pt)
PT (1) PT1093469E (pt)
WO (1) WO2000001734A1 (pt)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
KR100848121B1 (ko) * 1998-07-01 2008-07-24 캘리포니아 인스티튜트 오브 테크놀로지 선형 사이클로덱스트린 공중합체
AU2162700A (en) * 1998-12-04 2000-06-26 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
KR100371720B1 (ko) * 2000-07-03 2003-02-06 광주과학기술원 사이클로덱스트린 또는 이의 유도체와 이작용성 또는다작용성 히드록시 화합물의 축중합물, 및 이의 제조방법
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1275404A1 (en) * 2001-07-11 2003-01-15 SCA Hygiene Products AB Odour regulation in hygiene products
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP2325193A3 (en) 2001-11-02 2012-05-02 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
TW515107B (en) * 2001-12-25 2002-12-21 Solidlite Corp Power-saving light-emitting diode lamp
CN1305932C (zh) * 2002-02-22 2007-03-21 植入疗法公司 碳水化合物修饰的聚合物、其组合物及其应用
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CA2476589C (en) * 2002-02-27 2014-02-25 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
FR2842106B1 (fr) * 2002-07-11 2006-07-14 Centre Nat Rech Scient Dispersions aqueuses de particules nanometriques ou micrometriques pour l'encapsulation de composes chimiques
CA2818071C (en) * 2002-09-06 2015-08-18 Cerulean Pharma Inc. Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery
EP2277551B1 (en) * 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US8357377B2 (en) * 2002-10-09 2013-01-22 Suzie Hwang Pun Cyclodextrin-based materials, compositions and uses related thereto
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
MXPA05004580A (es) * 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
DK2216407T3 (en) 2003-03-07 2016-03-29 Alnylam Pharmaceuticals Inc therapeutic compositions
US20070179100A1 (en) * 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
ES2702942T3 (es) * 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
BRPI0418386A (pt) 2003-12-31 2007-05-22 Cydex Inc formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
EP1725660B1 (en) * 2004-03-05 2011-05-04 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of rnai agents
DE602004023765D1 (de) * 2004-03-12 2009-12-03 Trinity College Dublin Magnetoresistives medium
JP4339912B2 (ja) * 2004-09-18 2009-10-07 ミレ グリーン コンストラクション カンパニー リミテッド 遮集管渠の土砂流入防止装置
JP2008526229A (ja) * 2005-01-06 2008-07-24 ベニテック，インコーポレーテッド 幹細胞の維持のためのＲＮＡｉ剤
NZ560936A (en) 2005-02-03 2010-04-30 Benitec Inc RNAI expression constructs
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
ES2381201T3 (es) 2005-03-31 2012-05-24 Calando Pharmaceuticals, Inc. Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
CA2606002A1 (en) * 2005-04-28 2006-11-02 Benitec Limited Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
CA2633801A1 (en) * 2005-12-19 2007-06-28 Capsutech Ltd. Cyclodextrin-containing polymers and uses thereof
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
CA2642577A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2194068B1 (en) * 2007-09-28 2013-04-17 Nanodex INC. Cyclodextrin compound modified with folic acid, process for production thereof, drug delivery agent for targeting drug delivery system, pharmaceutical composition, and imaging agent
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
AU2009232355A1 (en) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of EPAS1 inhibitors
EP2770057A1 (en) 2008-04-15 2014-08-27 Protiva Biotherapeutics Inc. Silencing of CSN5 gene expression using interfering RNA
JP2011528910A (ja) * 2008-07-25 2011-12-01 アルニラム ファーマスーティカルズ インコーポレイテッド センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
WO2010099466A2 (en) 2009-02-26 2010-09-02 The Regents Of The University Of California A supramolecular approach for preparation of size controllable nanoparticles
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
TWI527901B (zh) 2010-07-08 2016-04-01 Bonac Corp A single stranded nucleic acid molecule used to control gene expression
EP2628801B1 (en) 2010-08-03 2015-01-07 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
JP5952815B2 (ja) 2010-08-04 2016-07-13 シズル バイオテクノロジー リミテッド ガンの診断および処置のための方法および化合物
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2780456A1 (en) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutic rna switches compositions and methods of use
RU2631599C2 (ru) 2011-12-14 2017-09-25 Дзе Джонс Хопкинс Юниверсити Наночастицы, легче проникающие в слизистую оболочку или вызывающие меньше воспаления
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2013103146A1 (ja) 2012-01-07 2013-07-11 株式会社ボナック アミノ酸骨格を有する一本鎖核酸分子
CN104936620B (zh) 2012-01-19 2019-08-09 约翰霍普金斯大学 增强粘膜渗透的纳米粒子调配物
CN104203985A (zh) * 2012-01-31 2014-12-10 天蓝制药公司 用于治疗性递送的环糊精类聚合物
US9598503B2 (en) 2012-04-18 2017-03-21 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
WO2015175539A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Engineering synthetic brain penetrating gene vectors
SI3142643T1 (sl) 2014-05-15 2019-11-29 Insmed Inc Postopki za zdravljenje pljučnih netuberkuloznih mikobakterijskih infekcij
CA2963271A1 (en) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
EP3250184A1 (en) 2015-01-27 2017-12-06 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
JP2019504178A (ja) * 2016-01-21 2019-02-14 アテン・ポラス・ライフサイエンシズ シクロデキストリンを主体とするポリマー、その方法、組成物、及び応用
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2018102769A1 (en) * 2016-12-01 2018-06-07 Bluelink Pharmaceuticals, Inc. Treatment of cancer
US20230192931A1 (en) * 2017-03-02 2023-06-22 Osaka University Host-group-containing polymerizable monomer, polymer material, method for producing same, and clathrate compound and method for producing same
WO2018169960A1 (en) 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
JPWO2019074110A1 (ja) 2017-10-13 2020-12-24 株式会社ボナック 一本鎖核酸分子およびその製造方法
US10765638B2 (en) 2017-11-03 2020-09-08 Yale University Particle formulation with polycation complex
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2020033951A1 (en) 2018-08-10 2020-02-13 Yale University Compositions and methods for embryonic gene editing in vitro
CN110016194A (zh) * 2019-04-16 2019-07-16 无锡纯宇环保制品有限公司 一种有利于水体净化的可降解塑料袋
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
US20220370488A1 (en) 2019-10-22 2022-11-24 The Johns Hopkins University Mucus penetrating particle compositions and methods of use thereof enhancing immune response
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
EP4228670A1 (en) 2020-10-15 2023-08-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
CN115160454A (zh) * 2021-04-01 2022-10-11 四川大学 一种基于聚-β-环糊精与金刚烷主客体作用的超分子多醛化合物及其制备方法
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2023064732A1 (en) 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
WO2023223787A1 (ja) * 2022-05-17 2023-11-23 リンテック株式会社 粘着性組成物、粘着剤、粘着シート、表示体および繰り返し屈曲デバイス

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32268E (en) * 1973-03-01 1986-10-21 Strategic Medical Research Corp. Therapeutic composition and method of therapeutically treating warm blooded animals therewith
JPS58167613A (ja) * 1982-03-26 1983-10-03 Mitsubishi Petrochem Co Ltd 水溶性シクロデキストリン含有重合体の製造法
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
AU624077B2 (en) * 1987-06-17 1992-06-04 Institute For Child Health Research Cloning of mite allergens
US4774329A (en) 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US4941996A (en) 1987-10-19 1990-07-17 Minnesota Mining And Manufacturing Company Inclusion complexes providing second harmonic generation
HU203899B (en) * 1988-05-03 1991-10-28 Forte Fotokemiai Ipar Process for producing gelatine-cyclodextreine polymeres
US4902788A (en) 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
JPH03221505A (ja) 1990-01-29 1991-09-30 Toppan Printing Co Ltd シクロデキストリンポリマーの合成方法及びシクロデキストリン膜の製造方法
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
DE4009825A1 (de) 1990-03-27 1991-10-02 Consortium Elektrochem Ind Wasserunloesliche cyclodextrin-polymerisate und verfahren zu deren herstellung
JPH0425505A (ja) * 1990-05-21 1992-01-29 Toppan Printing Co Ltd シクロデキストリンポリマー及びシクロデキストリン膜の製造方法
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
JPH04106101A (ja) * 1990-08-27 1992-04-08 Showa Denko Kk シクロデキストリンポリマーおよびその製造方法
EP0502194B1 (en) 1990-10-01 1997-10-01 Toppan Printing Co., Ltd. Cyclodextrin polymer and cyclodextrin film formed therefrom
JPH0586103A (ja) * 1990-10-01 1993-04-06 Toppan Printing Co Ltd シクロデキストリンポリマー
EP0513358B1 (en) * 1990-11-30 1997-10-01 Toppan Printing Co., Ltd. Process for producing cyclodextrin derivative and polymer containing cyclodextrin immobilized therein
CA2116431A1 (en) 1991-09-06 1993-03-18 Gurcharn S. Sidhu Composition and method for reducing cholesterol concentration
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
JP3221505B2 (ja) 1992-02-06 2001-10-22 日本信号株式会社 移動体の運行管理装置
IT1256134B (it) 1992-09-09 1995-11-29 Luigi Boltri Sali lipofili contenenti isotopi neutron attivabili e composizioni che li contengono
JPH07503757A (ja) 1992-11-30 1995-04-20 バイオ・キュア・インコーポレーテッド 重合性炭水化物エステル，それから得られるポリマー及びその用途
TW328535B (en) 1993-07-02 1998-03-21 Novartis Ag Functional photoinitiators and their manufacture
TW307775B (en) 1994-02-15 1997-06-11 Novartis Erfind Verwalt Gmbh Unsaturated carbohydrate derivatives, polymers thereof and their use
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5776842A (en) 1994-06-23 1998-07-07 Cellresin Technologies, Llc Cellulosic web with a contaminant barrier or trap
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
JP3830198B2 (ja) 1996-03-29 2006-10-04 東光薬品工業株式会社 超分子構造高分子集合体を用いた皮膚透過性インドメタシン外用剤
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
KR100848121B1 (ko) * 1998-07-01 2008-07-24 캘리포니아 인스티튜트 오브 테크놀로지 선형 사이클로덱스트린 공중합체
AU2162700A (en) * 1998-12-04 2000-06-26 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
DK1102785T3 (da) 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
EP1102784A4 (en) 1999-06-07 2009-12-30 Mirus Bio Corp A CONNECTION WITH A LABILES DISULFIDE TIE
EP1233671A4 (en) 1999-11-29 2005-11-02 Mirus Corp COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS

Also Published As

Publication number Publication date
MXPA01000206A (es) 2002-10-17
KR20010086293A (ko) 2001-09-10
DE69935982T2 (de) 2008-01-10
AU763114C (en) 2004-05-27
CY1106797T1 (el) 2012-05-23
AU763114B2 (en) 2003-07-10
CA2336390A1 (en) 2000-01-13
HU229473B1 (en) 2014-01-28
EP1764112B1 (en) 2013-02-13
JP2011006695A (ja) 2011-01-13
DK1093469T3 (da) 2007-09-17
ATE361321T1 (de) 2007-05-15
US6509323B1 (en) 2003-01-21
HUP0105472A3 (en) 2003-03-28
ES2403416T3 (es) 2013-05-17
EP1764112A2 (en) 2007-03-21
EP1764112A3 (en) 2007-05-23
IL140552A (en) 2006-10-31
KR100851315B1 (ko) 2008-08-08
CA2336390C (en) 2011-02-22
JP4741729B2 (ja) 2011-08-10
AU4830599A (en) 2000-01-24
HUP0105472A2 (hu) 2002-05-29
EP1093469A1 (en) 2001-04-25
JP2002519482A (ja) 2002-07-02
PT1093469E (pt) 2007-07-16
DK1764112T3 (da) 2013-03-11
CN1308639A (zh) 2001-08-15
BR9911754B1 (pt) 2010-07-13
DE69935982D1 (en) 2007-06-14
WO2000001734A1 (en) 2000-01-13
ES2285844T3 (es) 2007-11-16
EP1093469B1 (en) 2007-05-02
IL140552A0 (en) 2002-02-10
CN100365024C (zh) 2008-01-30

Similar Documents

Publication Publication Date Title
BR9911754A (pt) Copolìmero linear de ciclodextrina, composição terapêutica, composição de ciclodextrina, processos de preparo de um copolìmero linear de ciclodextrina, e de um copolìmero linear de ciclodextrina oxidada, processo para produzir um polìmero reticulado de ciclodextrina, e, processo de tratamento
BR9609176A (pt) Composi-{es de agente biolÄgico
DE69713335T2 (de) Polymere zur abgabe von stickstoffoxide in vivo
WO2002041837A3 (en) Treatment of mucositis
DE69528454T2 (de) Oberflächenmodifizierte endgruppen für biomedizinische polymere
ATE284715T1 (de) Embolisierende zubereitungen
DE69635026D1 (de) Varianten des menschlichen wachstumshormons
BR9501319A (pt) Composição tópica cosmetica e/ou dermatológica utilização desta composição e processo de tratamento cosmético
EP0426368A3 (en) Compositions containing derivatives of chitin for preventing adhesion
GR3035682T3 (en) Non-glycosylated fgf-4 and compositions containing the same.
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
DE69428350D1 (en) Polymere ionene als anthelminthika in tieren
DE68921002D1 (de) Verfahren und mittel zur präventiven behandlung von chirurgischen adhäsionen.
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
EP0842959A4 (en) MOLDED OBJECTS MADE OF FLUORINE COPOLYMER
EP0991371A4 (en) PROCESS FOR THE TREATMENT OF DENTAL PROSTHESES
UA29489C2 (uk) Композиція, що має бактерицидні та ранозагоюючі властивості
SU936512A1 (ru) Способ предотвращения свертывания крови

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2312 DE 28-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.